Literature DB >> 27756161

Modeling the chronic lymphocytic leukemia microenvironment in vitro.

Kyle Crassini1, Yandong Shen1, Stephen Mulligan1,2, O Giles Best1,2.   

Abstract

Microenvironments within the lymph node and bone marrow promote proliferation and drug resistance in chronic lymphocytic leukemia (CLL). Successful treatment of CLL must therefore target the leukemic cells within these compartments. A better understanding of the interaction between CLL cells and the tumor microenvironment has led to the development of in vitro models that mimic the mechanisms that support leukemic cell survival and proliferation in vivo. Employing these models as part of the pre-clinical evaluation of novel therapeutic agents enables a better approximation of their potential clinical efficacy. In this review we summarize the current literature describing how different aspects of the tumor microenvironment have been modeled in vitro and detail how these models have been employed to study the biology of the disease and potential efficacy of novel therapeutic agents.

Entities:  

Keywords:  Chronic lymphocytic leukemia; drug resistance; microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27756161     DOI: 10.1080/10428194.2016.1204654

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

2.  Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.

Authors:  Kallesh D Jayappa; Vicki L Gordon; Christopher G Morris; Briana Wilson; B Dharmaveer Shetty; Konrad J Cios; Puja C Arora; Krista M Isaac; Shekhar Saha; Timothy P Bender; Michael E Williams; Craig A Portell; Michael J Weber
Journal:  Blood Adv       Date:  2021-09-14

3.  Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells.

Authors:  Paschalis Athanasiadis; Aleksandr Ianevski; Sigrid S Skånland; Tero Aittokallio
Journal:  Methods Mol Biol       Date:  2022

Review 4.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

5.  Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.

Authors:  Sara E F Kost; Ali Saleh; Edgard M Mejia; Marina Mostafizar; Eric D J Bouchard; Versha Banerji; Aaron J Marshall; Spencer B Gibson; James B Johnston; Sachin Katyal
Journal:  Cancers (Basel)       Date:  2019-10-09       Impact factor: 6.639

6.  The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia.

Authors:  Maria I Edilova; Jaclyn C Law; Safoura Zangiabadi; Kenneth Ting; Achire N Mbanwi; Andrea Arruda; David Uehling; Methvin Isaac; Michael Prakesch; Rima Al-Awar; Mark D Minden; Ali A Abdul-Sater; Tania H Watts
Journal:  Oncoimmunology       Date:  2021-09-23       Impact factor: 8.110

Review 7.  Review of Venetoclax in CLL, AML and Multiple Myeloma.

Authors:  Masa Lasica; Mary Ann Anderson
Journal:  J Pers Med       Date:  2021-05-24

8.  First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.

Authors:  M Hojjat-Farsangi; A H Daneshmanesh; A S Khan; J Shetye; F Mozaffari; P Kharaziha; L-S Rathje; P Kokhaei; L Hansson; J Vågberg; S Byström; E Olsson; C Löfberg; C Norström; J Schultz; M Norin; T Olin; A Österborg; H Mellstedt; A Moshfegh
Journal:  Leukemia       Date:  2018-03-27       Impact factor: 11.528

9.  RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model.

Authors:  Hana Svozilová; Zdeněk Plichta; Vladimír Proks; Radana Studená; Jiří Baloun; Michael Doubek; Šárka Pospíšilová; Daniel Horák
Journal:  Int J Mol Sci       Date:  2021-02-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.